Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market Report 2026

Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market Overview

• Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices market size has reached to $47.56 billion in 2025 • Expected to grow to $62.83 billion in 2030 at a compound annual growth rate (CAGR) of 5.7% • Growth Driver: Growing Prevalence of Respiratory Diseases on COPD and Asthma Devices • Market Trend: Advancements In Smart Inhaler Technologies For Better Disease Control • North America was the largest region in 2025.

What Is Covered Under Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market?

Chronic obstructive pulmonary disease (COPD) and asthma devices refer to the medical devices used to manage and treat breathing and respiratory conditions. These devices help patients breathe more effectively, manage symptoms, and improve their quality of life. The main types of chronic obstructive pulmonary disease (COPD) and asthma devices are metered dose inhalers, drug powder inhalers, soft mist inhalers, jet nebulizers, ultrasonic nebulizers, and others. Metered Dose Inhalers are handheld devices that deliver medication in a precise dose as a spray or mist, typically used for treating conditions like COPD and asthma by inhaling the medication directly into the lungs. These devices are compact and portable, making them convenient for daily use by patients. The various indications include asthma and chronic obstructive pulmonary disease and are used in various applications such as hospitals, clinics, home care settings, research institutions, and others. The various end users include pediatric, adult, and geriatric.

What Is The Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market Growth Forecast?

The chronic obstructive pulmonary disease (copd) and asthma devices market size is expected to see strong growth in the next few years. It will grow to $62.83 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to aging population with higher respiratory risk, rising demand for home care respiratory devices, increasing awareness of early respiratory disease management, expansion of chronic disease management programs, growing access to respiratory care in emerging markets. Major trends in the forecast period include rising adoption of home-based respiratory care devices, increasing demand for portable and user-friendly inhalation devices, growing focus on long-term disease management solutions, expansion of device usage across pediatric and geriatric populations, increasing emphasis on treatment adherence and symptom control.

Global Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market Segmentation

1) By Type: Metered Dose Inhalers, Drug Powder Inhalers, Soft Mist Inhalers, Jet Nebulizers, Ultrasonic Nebulizers, Other Types 2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease 3) By Application: Hospitals, Clinics, Home Care Settings, Research Institutions, Other Applications 4) By End User: Pediatric, Adult, Geriatric Subsegments: 1) By Metered Dose Inhalers: Conventional MDI, Breath-Actuated MDI 2) By Drug Powder Inhalers: Dry Powder Inhalers (DPI), Multi-Dose DPI 3) By Soft Mist Inhalers: Respimat Soft Mist Inhalers, Other Soft Mist Devices 4) By Jet Nebulizers: Pneumatic Nebulizers, Venturi-Type Nebulizers 5) By Ultrasonic Nebulizers: Tabletop Ultrasonic Nebulizers, Portable Ultrasonic Nebulizers 6) By Other Types: Nebulizer Accessories, Spacer Devices

What Is The Driver Of The Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market?

The growing prevalence of respiratory diseases is expected to propel the growth of the chronic obstructive pulmonary disease (COPD) and asthma devices market going forward. Respiratory diseases encompass many conditions affecting the lungs and respiratory systems, such as asthma, chronic obstructive pulmonary disease, pneumonia, and lung cancer, impacting breathing and overall respiratory function. The growing prevalence of respiratory diseases is due to increasing air pollution levels, changing climate patterns affecting allergens and pathogens, and lifestyle habits such as smoking that compromise respiratory health. COPD and asthma devices play a crucial role in the comprehensive management and treatment of respiratory diseases, supporting patients to achieve better respiratory health and enhance their overall well-being. For instance, in December 2023, according to the National Center for Biotechnology Information, a US-based government agency, the number of COPD cases was expected to rise by 112 million, reaching a total of 592 million by 2050, which would represent 9.5% of the eligible population. Therefore, the growing prevalence of respiratory diseases drives the growth of the chronic obstructive pulmonary disease (COPD) and asthma devices markets.

Key Players In The Global Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market

Major companies operating in the chronic obstructive pulmonary disease (copd) and asthma devices market are AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Boehringer Ingelheim, Royal Philips NV, Teva Pharmaceuticals Industries Ltd., Omron Corporation, Smiths Medical Inc., Cipla Ltd., Chiesi Farmaceutici SpA, Sunovion Pharmaceuticals Inc., Drive DeVilbiss Healthcare, Pari Respiratory Equipment Inc., Allied Healthcare Products Inc., Clement Clarke International Ltd., Cohero Health Inc., Pneuma Respiratory Inc., Mundipharma International Ltd., 3M Health Care, Vyaire Medical Inc., Aerogen Ltd

Global Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market Trends and Insights

Major companies operating in the chronic obstructive pulmonary disease and asthma devices market are focusing on developing innovative solutions such as smart, sensor-enabled inhaler technologies to improve medication adherence, enable real-time symptom tracking, and support personalized respiratory disease management. Smart inhaler technologies involve integrating embedded sensors and digital connectivity features to capture inhalation data, monitor patient usage patterns, and deliver actionable insights to both patients and clinicians. For instance, in July 2023, Teva UK Ltd., a UK-based pharmaceutical company launched GoResp Digihaler, a digitally connected inhaler designed to record inhalation parameters, provide real-time feedback, and support improved disease control through data-driven patient engagement. The device helps enhance treatment outcomes by enabling remote monitoring, offering clinicians deeper visibility into patient adherence trends, and strengthening long-term disease management for individuals with chronic respiratory conditions.

What Are Latest Mergers And Acquisitions In The Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market?

In January 2025, Molex LLC, a US-based global electronics and connectivity solutions company, completed the acquisition of Vectura Group for an undisclosed amount. Through this acquisition, Molex aims to strengthen its healthcare and medical device capabilities by integrating Vectura’s advanced inhalation and drug-delivery technologies to expand its portfolio of connected, patient-centric respiratory solutions. Vectura Group is a UK-based pharmaceutical and medical device company specializing in inhaled drug-delivery systems for COPD, asthma, and other respiratory conditions.

Regional Outlook

North America was the largest region in the chronic obstructive pulmonary disease (COPD) and asthma devices market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market?

The chronic obstructive pulmonary disease (COPD) and asthma devices market consists of sales of spacer devices, peak flow meters, oxygen therapy equipment, pulse oximeters, and airway clearance devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.